Multiple Myeloma Research Consortium

The Multiple Myeloma Research Foundation (MMRF) has enrolled the first patient in the Horizon Clinical Trials Program, an adaptive platform trial across the Multiple Myeloma Research Consortium (MMRC). The trial aims to determine the best combination, sequence, and duration of therapy for patients with relapsed and refractory myeloma. The first arm will evaluate dosing approaches with Tecvayli (teclistamab), manufactured by Johnson & Johnson.

The Multiple Myeloma Research Foundation (MMRF) has enrolled the first patient in the Horizon Clinical Trials Program, an adaptive platform trial across the Multiple Myeloma Research Consortium (MMRC). The trial aims to determine optimal treatment combinations, sequences, and durations for patients with relapsed and refractory myeloma. Johnson & Johnson supports the research with Tecvayli (teclistamab).

The Multiple Myeloma Research Foundation (MMRF) announced the first patient enrollment in the Horizon Clinical Trials Program, an adaptive platform trial across the Multiple Myeloma Research Consortium (MMRC). The trial aims to determine optimal treatment combinations, sequences, and durations for critical patient populations, including those with relapsed and refractory myeloma.